Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology.

Publication date: Jan 01, 2020

Analogues of the anti-tuberculosis drug bedaquiline, bearing a 3,5-dimethoxy-4-pyridyl C-unit, retain high anti-bacterial potency yet exert less inhibition of the hERG potassium channel, in vitro, than the parent compound. Two of these analogues (TBAJ-587 and TBAJ-876) are now in preclinical development. The present study further explores structure-activity relationships across a range of related 3,5-disubstituted-4-pyridyl C-unit bedaquiline analogues of greatly varying lipophilicity (clogP from 8.16 to 1.89). This broader class shows similar properties to the 3,5-dimethoxy-4-pyridyl series, being substantially more potent in vitro and equally active in an in vivo (mouse) model than bedaquiline, while retaining a lower cardiovascular risk profile through greatly attenuated hERG inhibition.

Sutherland, H.S., Tong, A.S.T., Choi, P.J., Blaser, A., Franzblau, S.G., Cooper, C.B., Upton, A.M., Lotlikar, M., Denny, W.A., and Palmer, B.D. Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology. 07505. 2020 Bioorg Med Chem (28):1.

Concepts Keywords
Cardiovascular Anti tuberculosis
ClogP Chemistry
HERG Physical sciences
Lipophilicity Natural sciences
Mouse Lithium compounds
Pharmacology Non-nucleophilic bases
Potassium Tuberculosis
Preclinical Development RTT
Pyridyl Bedaquiline
Tuberculosis Lithium tetramethylpiperidide
HERG
Lithium diisopropylamide
Alpha

Semantics

Type Source Name
drug DRUGBANK Bedaquiline
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Potassium
disease MESH development
drug DRUGBANK Chlorhexadol
drug DRUGBANK Oxygen
drug DRUGBANK Methyl isocyanate

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *